NCT06193031View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 17, 2015

Primary Completion Date

December 18, 2015

Study Completion Date

December 18, 2015

Conditions

Healthy Volunteers

Interventions

DRUG

C16TR

Administered as inhalation using a Philips Micro device inhaler.

DRUG

Placebo

Phosphate buffered saline (PBS) administered using Philips Micro device inhaler.

DRUG

Tyvaso®

Administered as inhalation.

Trial Locations (1)

91206

USA001, Los Angeles

All Listed Sponsors

lead

Insmed Incorporated

INDUSTRY

NCT06193031 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants | Biotech Hunter | Biotech Hunter